Miller Ross A, Mody Dina R, Tams Kimberlee C, Thrall Michael J
From the University of South Dakota Pathology Residency Program, Sioux Falls (Dr Miller); the Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas (Drs Mody and Thrall); and the Sanford Health Pathology Clinic, University of South Dakota Medical Center, Sioux Falls (Dr Tams). Dr Miller is now with the Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas.
Arch Pathol Lab Med. 2015 Nov;139(11):1431-6. doi: 10.5858/arpa.2014-0633-OA. Epub 2015 May 7.
The Papanicolaou (Pap) test has indisputably decreased cervical cancer mortality, as rates have declined by up to 80% in the United States since its implementation. However, the Pap test is considered less sensitive for detecting glandular lesions than for detecting those of squamous origin. Some studies have even suggested an increasing incidence of cervical adenocarcinoma, which may be a consequence of a relatively reduced ability to detect glandular lesions with cervical cancer screening techniques.
To evaluate the detection rate of glandular lesions with screening techniques currently used for cervical cancer screening and to provide insight as to which techniques are most efficacious in our study population.
We retrospectively reviewed any available cytology, human papillomavirus (HPV), and histologic malignancy data in patients diagnosed with adenocarcinoma in situ and adenocarcinoma from 2 geographically and socioeconomically disparate hospital systems. Identified patients having had a negative/unsatisfactory Pap test within 5 years of adenocarcinoma in situ or adenocarcinoma tissue diagnosis were considered Pap test screening failures. Patients with negative HPV tests on cytology samples were considered HPV screening failures.
One hundred thirty cases were identified (age range, 22-93 years); 39 (30%) had no Pap history in our files. Eight of 91 remaining cases (8.8%) were screening failures. The detected sensitivity for identifying adenocarcinoma in situ/adenocarcinoma in this study was 91.2% by cytology alone and 92.3% when incorporating HPV testing. The most common cytologic diagnosis was atypical glandular cells (25 cases), and those diagnosed with adenocarcinoma were 7.4 years older than those diagnosed with adenocarcinoma in situ (50.3 versus 42.9 years). Nine of 24 HPV-tested cases (37.5%) were called atypical squamous cell of undetermined significance on cytology.
Our results highlight the importance of combined Pap and HPV cotesting. Although the number of cases identified is relatively small, our data suggest screening for squamous lesions facilitates the recognition of glandular lesions in the cervix. Additionally, increased use of combined Pap and HPV cotesting may decrease detection failure rates with regard to glandular lesions.
巴氏涂片检查无疑降低了宫颈癌死亡率,自其在美国实施以来,死亡率已下降高达80%。然而,巴氏涂片检查在检测腺性病变方面被认为不如检测鳞状病变敏感。一些研究甚至表明宫颈腺癌的发病率在上升,这可能是宫颈癌筛查技术检测腺性病变能力相对下降的结果。
评估目前用于宫颈癌筛查的技术对腺性病变的检测率,并了解在我们的研究人群中哪些技术最有效。
我们回顾性分析了来自两个地理和社会经济情况不同的医院系统中诊断为原位腺癌和腺癌患者的所有可用细胞学、人乳头瘤病毒(HPV)和组织学恶性数据。在原位腺癌或腺癌组织诊断前5年内巴氏涂片检查结果为阴性/不满意的患者被视为巴氏涂片检查筛查失败。细胞学样本HPV检测结果为阴性的患者被视为HPV筛查失败。
共识别出130例病例(年龄范围22 - 93岁);我们的档案中有39例(30%)没有巴氏涂片检查记录。其余91例病例中有8例(8.8%)筛查失败。在本研究中,仅通过细胞学检测原位腺癌/腺癌的敏感性为91.2%,结合HPV检测时为92.3%。最常见的细胞学诊断是非典型腺细胞(25例),诊断为腺癌的患者比诊断为原位腺癌的患者大7.4岁(50.3岁对42.9岁)。24例接受HPV检测的病例中有9例(37.5%)在细胞学上被诊断为意义不明确的非典型鳞状细胞。
我们的结果突出了巴氏涂片和HPV联合检测的重要性。尽管识别出的病例数量相对较少,但我们的数据表明筛查鳞状病变有助于识别宫颈腺性病变。此外,增加巴氏涂片和HPV联合检测的使用可能会降低腺性病变的检测失败率。